+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COVID-19 Vaccine and Therapeutics Pipeline Analysis 2020

  • PDF Icon


  • July 2020
  • Region: Global
  • The Business Research Company
  • ID: 5129278
COVID-19 Vaccine And Therapeutics Pipeline Analysis 2020 provides the strategists, marketers and senior management with the critical information they need to assess the global COVID-19 vaccine & therapeutics pipeline analysis 2020 market.

This report focuses on COVID-19 vaccine & therapeutics pipeline analysis 2020 market which is experiencing strong growth. The report gives a guide to the COVID-19 vaccine & therapeutics pipeline analysis 2020 market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis


Where is the largest and fastest growing market for the COVID-19 vaccine & therapeutics pipeline analysis 2020? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The COVID-19 Vaccine & Therapeutics Pipeline Analysis 2020 market global answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider COVID-19 vaccine & therapeutics pipeline analysis 2020 market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
  • The COVID-19 vaccine & therapeutics pipeline analysis 2020 market section of the report gives context. It compares the COVID-19 vaccine & therapeutics pipeline analysis 2020 market with other segments of the COVID-19 vaccine & therapeutics pipeline analysis 2020 market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, COVID-19 vaccine & therapeutics pipeline analysis 2020 indicators comparison.


Markets Covered:
1) By Product Type: Small Molecules, Biologics, Blood & Plasma Derivatives, Monoclonal Antibodies, Vaccines, Others
2) By Phase Of Development: Preclinical Therapeutics & Vaccines, Clinical Studies
3) By Treatment Mechanism & Route Of Administration: Mechanism Of Action And By Route Of Administration
4) By Type Of Sponsor: Pharma/Biotech Company, Academic Research/Institution, Others (such as Government Organizations and CROs)

Companies Mentioned: CanSino Biologics; Moderna; Inovio Pharmaceuticals; Regeneron; Gilead Sciences

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1. Executive Summary
2. Disease Overview
2.1. Novel Coronavirus Etiology and Pathogenesis
2.2. Novel Human Coronavirus (ClOVID-19) Clinical Features-Signs and Symptoms
3. Disease Epidemiology and Epidemic Statistics for Major countries
4. Global Pipeline Analysis of COVID-19 Therapeutics and Vaccines
4.1 Global Pipeline Analysis, By Product Type
4.1.1 Small Molecules
4.1.2 Biologics Blood & Plasma Derivatives Monoclonal Antibodies Vaccines Others
4.2 Global Pipeline Analysis, By Phase of development
4.2.1 Preclinical Therapeutics & Vaccines
4.2.2 Clinical Studies Clinical Phase I, II, III
4.3 Global Pipeline Analysis, By Treatment Mechanism & Route of Administration
4.3.1 Mechanism of Action Viral Replication Inhibitors Protease Inhibitors Immunostimulants Other Mechanism of Action
4.3.2 Route of Administration Oral Intravenous Subcutaneous Other Route of Administration
4.4 Global Pipeline Analysis, By Type of Sponsor
4.4.1 Pharma/Biotech Company
4.4.2 Academic Research/Institution
4.4.3 Others such as Government Organizations and CROs
5. Competitive Landscape for Late Stage Therapeutics and Vaccine
5.1 Company Overview
5.2 Product Description
5.3 Research and Development
5.3.1 Non-Clinical Studies
5.3.2 Clinical Studies
5.3.3 Highest/Late Stage Development Activities
5.4 Licensing and Collaboration Agreements
5.5 Milestones & Future Plans
6. Regulatory Framework for COVID-19 Therapeutics and Vaccines Marketing Approvals
6.1 Regulatory Framework in the USA
6.2 Regulatory Framework in EU and Other Countries
7. Recommendations & Conclusion

Executive Summary

Major players in the COVID-19 vaccine and therapeutics pipeline analysis market are CanSino Biologics, Moderna, Inovio Pharmaceuticals, Regeneron, Gilead Sciences, GlaxoSmithKline, Medicago Inc., Sanofi, University of Oxford, and Altimmune.

The COVID-19 vaccine and therapeutics pipeline analysis market covered in this report is segmented by product type into small molecules, biologics, blood & plasma derivatives, monoclonal antibodies, vaccines, others. It is also segmented by the phase of development into preclinical therapeutics & vaccines, clinical studies, by treatment mechanism & route of administration, and by type of sponsor into pharma/biotech company, academic research/institution, others.

The COVID-19 vaccine and therapeutics pipeline analysis market report provides an analysis of the coronavirus (COVID-19) therapeutics and vaccines under development. The report includes existing vaccines developed against MERS-CoV and SARS-CoV. The novel coronavirus-2019 (nCoV-19) has been named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses (ICTV) due to its genetic similarity with the coronavirus responsible for the 2003 SARS outbreak. Currently, government agencies, international health authorities and institutions and biopharmaceutical companies worldwide are focusing on developing vaccines/drugs to prevent or treat the COVID-19 infection.

Ever since the coronavirus hit the world as a global pandemic, many key vaccine developers are collaborating to develop potential COVID-19 vaccine against coronavirus.

Most recently, on 21st May 2020, CanSino Biologics Inc. and Precision NanoSystems announced a co-development agreement of an mRNA lipid nanoparticle (mRNA-LNP) vaccine against COVID-19. The parties will leverage Precision NanoSystems's proprietary RNA vaccine platform, comprising of lipid nanoparticle delivery system and the NanoAssemblr® manufacturing technology, to rapidly advance a COVID-19 mRNA-LNP vaccine candidate towards human clinical testing and pursuant to regulatory approvals, and commercialization in different regions. Precision NanoSystems will be responsible for the development of the mRNA-LNP vaccine and CanSinoBIO will be responsible for pre-clinical testing, human clinical trials, regulatory approval and commercialization.

Similarly, on May 19, 2020, IPharmaJet®, the maker of innovative, needle-free injection technology announced that its Needle-free Injection System technology will be used to deliver a messenger RNA (mRNA) vaccine against SARS-CoV-2. The vaccine is being developed by Abnova Corporation, the world's largest antibody manufacturer, based in Taiwan.

The development of potential drugs and vaccines for COVID-19 is progressing quickly. There is a massive increase in COVID-19 drugs and vaccines pipeline owing to the urgent need to contain the spread of disease. Government agencies, global health authorities and institutes, and biopharmaceutical companies are focusing on remedies to treat the patients and control the infection spread. Increasing every day, 450+ potential therapeutic candidates are under investigation. While two-thirds of the pipeline account for therapeutic drugs, the remaining one-third accounts for vaccines.

Of the confirmed active vaccine candidates, nearly 70% are being developed by private/industry developers, with the remaining 30% of projects being led by the academic, public sector and other non-profit organizations. Most COVID-19 vaccine development activity is in North America, with around 36 (46%) developers of the confirmed active vaccine candidates. China constitutes 18% with 14 developers, while, Asia excluding China and Europe also constitute 18% each with 14 developers in each region, respectively.

The long and costly drug development process is anticipated to limit the growth of the COVID-19 vaccine & therapeutics. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the average cost of research and development of a new drug is approximately $2.6 billion. Moreover, the stringent regulations imposed by the various regulatory authorities such as European Medicines Agency and the US Food and Drug Administration (FDA) in regards with clinical trials during the COVID-19 outbreak attributing to the safety of trial participants, maintaining compliance with good clinical practice, and minimizing risks to trial integrity is a major challenge faced by the COVID-19 vaccine and therapeutics market.

The compounds and medications that are under investigation can be grouped into three broad categories – antivirals, immune-system based, and vaccines. The anti-virals including Darunavir, Favipiravir, Hydroxychloroquine and chloroquine, Lopinavir, and Remdesivir (GS-5734), immune system-related therapies including Tocilizumab, Tocilizumab, and Vitamin C, and other medications are currently being evaluated as therapies. Three key drugs are currently in phase III, of which are two small molecule-based drugs, Remdesivir by Gilead Sciences Inc. and Favipiravir by Fujifilm Toyama Chemical Co Ltd, and Sarilumab, a monoclonal antibody by Regeneron Pharmaceutical. With regards to the prophylactic vaccine pipeline, more than 90% are in early-stage development (discovery and preclinical), and only three in Phase II. These three COVID-19 vaccines are being developed by Sinovac Biotech Ltd, the University of Oxford, and the third vaccine, named CIGB-2020, is being developed by the Center for Genetic Engineering and Biotechnology.

According to the European Centre for Disease Prevention and Control, worldwide, there are over 10.8 million cases of COVID-19. Globally, R&D spending has increased to find a potential drug or vaccine to combat this pandemic. Currently, there is no approved targeted therapy for patients with COVID-19. However, an array of drugs approved for other indications as well as several new investigational drugs are being studied in several hundred clinical trials. The increased R&D spending has contributed to the invention/discovery of more than 400 unique drugs to treat COVID-19 among which 298 are therapeutic drugs and 140 prophylactic vaccines that are spread across all stages of development (Discovery, Preclinical, Phase I, Phase II, and Phase III). As of June 2020, over 2,341 clinical trials are investigating potential therapies for COVID-19, of which nearly 800 are interventional trials.

Other Collaborations:
  • Moderna and Lonza also announced their strategic collaboration to manufacture Moderna’s Vaccine (mRNA-1273) against novel coronavirus.
  • AstraZeneca and the University of Oxford made an agreement for the global development and distribution of the University’s potential recombinant adenovirus vaccine aimed at preventing COVID-19 infection from SARS-CoV-2.
  • Catalent signed an agreement with Johnson & Johnson to be U.S. manufacturing partner for lead COVID-19 vaccine candidate

Companies Mentioned

A selection of companies mentioned in this report includes:

  • CanSino Biologics
  • Moderna
  • Inovio Pharmaceuticals
  • Regeneron
  • Gilead Sciences
  • Altimmune
  • GlaxoSmithKline
  • Medicago Inc.
  • Sanofi
  • University of Oxford
  • Novavax
  • Roche
  • Johnson and Johnson/Janssen Pharmaceutical
  • APEIRON Biologics
  • Cipla Limited
  • Takis Biotech/Applied DNA Sciences/Evvivax
  • Algernon
  • Zydus Cadila
  • Abbvie
  • Epivax
  • Dynavax
  • Abcellera
  • Pfizer
  • Takeda
  • Vaxart
  • University of Pittsburgh
  • Clover Biopharmaceuticals
  • Medicago